Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
Main Article Content
Keywords
roflumilast cream, roflumilast foam, psoriasis, seborrheic dermatitis, atopic dermatitis, local tolerability
References
2. Danby SG, et al. J Dermatolog Treat 2022;33:685–698.
3. Lessmann H, et al. Contact Dermatitis 2005;53:247–259.
4. Zirwas MJ, et al. JAMA Dermatol 2023;159:613–620. 5. ZORYVE (roflumilast) cream prescribing information. Westlake Village, CA: Arcutis Biotherapeutics, Inc; July, 2022. 6. Lebwohl MG, et al. JAMA 2022;328:1073–1084.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.